Abstract
ment for differences in baseline and operative characteristics, administration of the current formulation of PPC brand heparin was associated with the highest likelihood of receiving FFP (A OR 1.00; B OR 1.73, p 0.04; C OR 1.94, p 0.01; D OR 1.01, p 0.98) and PLT (A OR 1.00; B OR 1.88, p 0.03; C OR 2.44, p 0.001; D OR 1.26, p 0.42). CONCLUSION: In patients undergoing cardiac surgery, PPC brand heparin resulted in increased heparin dosing, peri-operative bleeding and peri-operative blood product transfusion in patients undergoing cardiac surgery. The results of this study suggest that an alternative to PPC brand heparin be used when placing patients on cardiopulmonary bypass.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
